Plasma apolipoprotein M responses to statin and fibrate administration in type 2 diabetes mellitus

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Plasma apolipoprotein M responses to statin and fibrate administration in type 2 diabetes mellitus. / Kappelle, Paul J W H; Ahnström, Josefin; Dikkeschei, Bert D; de Vries, Rindert; Sluiter, Wim J; Wolffenbuttel, Bruce H R; van Tol, Arie; Nielsen, Lars Bo; Dahlbäck, Björn; Dullaart, Robin P F.

In: Atherosclerosis, Vol. 213, No. 1, 2010, p. 247-250.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Kappelle, PJWH, Ahnström, J, Dikkeschei, BD, de Vries, R, Sluiter, WJ, Wolffenbuttel, BHR, van Tol, A, Nielsen, LB, Dahlbäck, B & Dullaart, RPF 2010, 'Plasma apolipoprotein M responses to statin and fibrate administration in type 2 diabetes mellitus', Atherosclerosis, vol. 213, no. 1, pp. 247-250. https://doi.org/10.1016/j.atherosclerosis.2010.07.048

APA

Kappelle, P. J. W. H., Ahnström, J., Dikkeschei, B. D., de Vries, R., Sluiter, W. J., Wolffenbuttel, B. H. R., van Tol, A., Nielsen, L. B., Dahlbäck, B., & Dullaart, R. P. F. (2010). Plasma apolipoprotein M responses to statin and fibrate administration in type 2 diabetes mellitus. Atherosclerosis, 213(1), 247-250. https://doi.org/10.1016/j.atherosclerosis.2010.07.048

Vancouver

Kappelle PJWH, Ahnström J, Dikkeschei BD, de Vries R, Sluiter WJ, Wolffenbuttel BHR et al. Plasma apolipoprotein M responses to statin and fibrate administration in type 2 diabetes mellitus. Atherosclerosis. 2010;213(1):247-250. https://doi.org/10.1016/j.atherosclerosis.2010.07.048

Author

Kappelle, Paul J W H ; Ahnström, Josefin ; Dikkeschei, Bert D ; de Vries, Rindert ; Sluiter, Wim J ; Wolffenbuttel, Bruce H R ; van Tol, Arie ; Nielsen, Lars Bo ; Dahlbäck, Björn ; Dullaart, Robin P F. / Plasma apolipoprotein M responses to statin and fibrate administration in type 2 diabetes mellitus. In: Atherosclerosis. 2010 ; Vol. 213, No. 1. pp. 247-250.

Bibtex

@article{566646108e1844e5bd2ba7d09807c0e4,
title = "Plasma apolipoprotein M responses to statin and fibrate administration in type 2 diabetes mellitus",
abstract = "Purpose: Plasma apolipoproteinM(apoM) is potentially anti-atherogenic, and has been found to be associated positively with plasma total, LDL and HDL cholesterol in humans.ApoMmay, therefore, be intricately related to cholesterol metabolism. Here, we determined whether plasma apoM is affected by statin or fibrate administration in patients with diabetes mellitus. Methods: Fourteen type 2 diabetic patients participated in a placebo-controlled crossover study which included three 8-week treatment periods with simvastatin (40mg daily), bezafibrate (400mg daily), and their combination. Results: ApoM was decreased by 7% in response to simvastatin (P < 0.05 from baseline and placebo), and remained unchanged during bezafibrate and combined simvastatin + bezafibrate administration. Plasma apoM concentrations correlated positively with apoB-containing lipoprotein measures at baseline and during placebo (P < 0.02 to P < 0.001), but these relationships were lost during all lipid lowering treatment periods. Conclusions: This study suggests that, even though plasma apoM is lowered by statins, apoM metabolism is to a considerable extent independent of statin- and fibrate-affected pathways involved in cholesterolhomeostasis.",
keywords = "Apolipoproteins, Bezafibrate, Blood Pressure, Cholesterol, Cross-Over Studies, Diabetes Mellitus, Type 2, Double-Blind Method, Fibric Acids, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Hypolipidemic Agents, Lipocalins, Male, Middle Aged, Placebos, Simvastatin",
author = "Kappelle, {Paul J W H} and Josefin Ahnstr{\"o}m and Dikkeschei, {Bert D} and {de Vries}, Rindert and Sluiter, {Wim J} and Wolffenbuttel, {Bruce H R} and {van Tol}, Arie and Nielsen, {Lars Bo} and Bj{\"o}rn Dahlb{\"a}ck and Dullaart, {Robin P F}",
note = "Copyright {\textcopyright} 2010 Elsevier Ireland Ltd. All rights reserved.",
year = "2010",
doi = "10.1016/j.atherosclerosis.2010.07.048",
language = "English",
volume = "213",
pages = "247--250",
journal = "Atherosclerosis",
issn = "0021-9150",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

RIS

TY - JOUR

T1 - Plasma apolipoprotein M responses to statin and fibrate administration in type 2 diabetes mellitus

AU - Kappelle, Paul J W H

AU - Ahnström, Josefin

AU - Dikkeschei, Bert D

AU - de Vries, Rindert

AU - Sluiter, Wim J

AU - Wolffenbuttel, Bruce H R

AU - van Tol, Arie

AU - Nielsen, Lars Bo

AU - Dahlbäck, Björn

AU - Dullaart, Robin P F

N1 - Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.

PY - 2010

Y1 - 2010

N2 - Purpose: Plasma apolipoproteinM(apoM) is potentially anti-atherogenic, and has been found to be associated positively with plasma total, LDL and HDL cholesterol in humans.ApoMmay, therefore, be intricately related to cholesterol metabolism. Here, we determined whether plasma apoM is affected by statin or fibrate administration in patients with diabetes mellitus. Methods: Fourteen type 2 diabetic patients participated in a placebo-controlled crossover study which included three 8-week treatment periods with simvastatin (40mg daily), bezafibrate (400mg daily), and their combination. Results: ApoM was decreased by 7% in response to simvastatin (P < 0.05 from baseline and placebo), and remained unchanged during bezafibrate and combined simvastatin + bezafibrate administration. Plasma apoM concentrations correlated positively with apoB-containing lipoprotein measures at baseline and during placebo (P < 0.02 to P < 0.001), but these relationships were lost during all lipid lowering treatment periods. Conclusions: This study suggests that, even though plasma apoM is lowered by statins, apoM metabolism is to a considerable extent independent of statin- and fibrate-affected pathways involved in cholesterolhomeostasis.

AB - Purpose: Plasma apolipoproteinM(apoM) is potentially anti-atherogenic, and has been found to be associated positively with plasma total, LDL and HDL cholesterol in humans.ApoMmay, therefore, be intricately related to cholesterol metabolism. Here, we determined whether plasma apoM is affected by statin or fibrate administration in patients with diabetes mellitus. Methods: Fourteen type 2 diabetic patients participated in a placebo-controlled crossover study which included three 8-week treatment periods with simvastatin (40mg daily), bezafibrate (400mg daily), and their combination. Results: ApoM was decreased by 7% in response to simvastatin (P < 0.05 from baseline and placebo), and remained unchanged during bezafibrate and combined simvastatin + bezafibrate administration. Plasma apoM concentrations correlated positively with apoB-containing lipoprotein measures at baseline and during placebo (P < 0.02 to P < 0.001), but these relationships were lost during all lipid lowering treatment periods. Conclusions: This study suggests that, even though plasma apoM is lowered by statins, apoM metabolism is to a considerable extent independent of statin- and fibrate-affected pathways involved in cholesterolhomeostasis.

KW - Apolipoproteins

KW - Bezafibrate

KW - Blood Pressure

KW - Cholesterol

KW - Cross-Over Studies

KW - Diabetes Mellitus, Type 2

KW - Double-Blind Method

KW - Fibric Acids

KW - Humans

KW - Hydroxymethylglutaryl-CoA Reductase Inhibitors

KW - Hypolipidemic Agents

KW - Lipocalins

KW - Male

KW - Middle Aged

KW - Placebos

KW - Simvastatin

U2 - 10.1016/j.atherosclerosis.2010.07.048

DO - 10.1016/j.atherosclerosis.2010.07.048

M3 - Journal article

C2 - 20828695

VL - 213

SP - 247

EP - 250

JO - Atherosclerosis

JF - Atherosclerosis

SN - 0021-9150

IS - 1

ER -

ID: 33815164